Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399590 | 0.90 | DRD4 (0.44) | GAACYP2D6MEN1KMT2ATSHR | |
| SCHEMBL20399589 | 0.90 | DRD4 (0.44) | GAACYP2D6MEN1KMT2ATSHR | |
| SCHEMBL18668633 | 0.84 | RORC (0.46) | KDM4ERORC | |
| SCHEMBL18668635 | 0.84 | RORC (0.46) | KDM4ERORC | |
| SCHEMBL29597428 | 0.84 | RORC (0.46) | KDM4ERORC | |
| SCHEMBL24276430 | 0.84 | RORC (0.46) | KDM4ERORC | |
| SCHEMBL6324844 | 0.81 | GAA (0.51) | GAACYP2D6MEN1KMT2ATSHR | |
| SCHEMBL6318884 | 0.81 | S1PR5 (0.48) | GAACYP2D6MEN1KMT2ATSHR | |
| SCHEMBL14801926 | 0.81 | CYP2D6 (0.42) | GAACYP2D6TSHRS1PR1S1PR5 | |
| SCHEMBL14801925 | 0.81 | CYP2D6 (0.42) | GAACYP2D6TSHRS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353181-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208601-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | GAA 272/4885CYP2D6 3810/4885MEN1 1628/4885 |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | GAA 272/4885CYP2D6 3810/4885MEN1 1628/4885 |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN10, ATXN2L | GAA 152/4885CYP2D6 3626/4885MEN1 1913/4885 |
| US-20180208601-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | GAA 260/4885CYP2D6 3735/4885MEN1 1558/4885 |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | GAA 260/4885CYP2D6 3735/4885MEN1 1558/4885 |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | GAA 260/4885CYP2D6 3735/4885MEN1 1558/4885 |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | GAA 260/4885CYP2D6 3735/4885MEN1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.